Stockwatch: Game, Pharmasset, and Match?
This article was originally published in Scrip
Just at the moment when markets are more focused on sovereign debt crises and Wall Street is thinking about squatters on its doorstep and looking forward to Thanksgiving, Gilead Sciences steps up and makes an audacious all cash $11 billion bid for Pharmasset. The planned acquisition, which has the full backing of the Pharmasset board, raises more questions than it answers.
You may also be interested in...
Gilead was among the companies that reported 2Q results last week but left investors wondering what more lay beneath the announcements. At this point in earnings season, investors’ models are as current as they can ever be, but uncertainty still prevails.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.